再発難治性多発性骨髄腫(RRMM)における骨髄外病変(EMD)および傍骨髄性病変(PMD)に対する放射線療法誘発性免疫プライミングによるエルラナタマブ(Elra)増強の第2相臨床試験「PRIME-EMD-PMD」
再発難治性多発性骨髄腫(RRMM)における髄外病変(EMD)および傍骨髄病変(PMD)に対する放射線療法誘発性免疫プライミングによるエルラナタマブ(Elra)増強の第2相臨床試験「PRIME-EMD-PMD」
To learn if low doses of radiation therapy can help the drug elranatamab enhance the killing effect of the cancer cells.
調査の概要
状態
介入・治療
詳細な説明
Primary Objectives To evaluate the efficacy of RT-induced immune priming to enhance Elranatamab (Elra) in RRMM with EMD or PMD as measured by overall response rate (ORR) at 3 months
Secondary Objectives To describe adverse events (AEs). To determine time to next treatment (TTNT). To evaluate progression-free survival (PFS). To determine overall survival (OS). To estimate quality of life (QOL). To assess local control to the irradiated lesions To determine differences in response in patients with EMD vs PMD To determine differences in response in patients High Risk (HR) vs Standard Risk (SR) disease
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Christine Ye, MD
- 電話番号:832-748-6369
- メール:jcye@mdanderson.org
研究場所
-
-
Texas
-
Houston、Texas、アメリカ、77030
- 募集
- MD Anderson Cancer Center
-
主任研究者:
- Christine Ye, MD
-
コンタクト:
- Christine Ye, MD
- 電話番号:832-748-6369
- メール:jcye@mdanderson.org
-
-
参加基準
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria
-
RRMM exposed to IMID, PI, anti-CD38 mAb, relapsed or refractory to at least one prior line of therapy (LOT), progressed on or after the last regimen:
- Relapsed disease: progressive disease (PD) >60 days after cessation of prior therapy
- Refractory disease: PD <=60 days after cessation of prior therapy, <25% reduction in paraprotein (monoclonal protein [M-protein] or serum free light chains [sFLC]) or measurements of EMD/PMD
-
Diagnosis of relapsed or refractory multiple myeloma as indicated by progression by IMWG criteria
-
At least one locus of EMD or PMD present on imaging (either PET/CT or magnetic resonance imaging [MRI]):
-
EMD: extramedullary plasmacytoma, not a contiguous extension from a bone lesion.
-
PMD: paraskeletal plasmacytoma, contiguous extension from a bone lesion At least one locus of EMD/PMD that was not previously radiated and can be treated with radiation
-
Hematology (supportive care is allowed, including transfusions and granulocyte colony stimulating factor (G-CSF), if cytopenia is deemed secondary to myeloma disease burden):
-
Hemoglobin (Hgb) >=7g/dL
-
Platelet>=50K/uL
-
Absolute neutrophil count (ANC) >=0.75K/uL
-
Chemistry:
-
Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) <=2.5 x upper
-
limit of normal (ULN)
-
Total bilirubin (TBili) <=1.5ULN (except for a known history of Gilbert syndrome)
-
Creatinine clearance (CrCL) >=30mL/min/1.73m2
-
Eastern Cooperative Oncology Group Performance Status (ECOG PS) <=2, unless ECOG PS due to pain/morbidity secondary to underlying myeloma disease, with the potential of improved ECOG PS to <=2.
-
All participants must be either
-
Not of childbearing potential, or
-
Practicing at least 1 highly effective method of contraception until 6 months after the last dose of study treatment.
-
Childbearing age female participantsmust have a negative serum pregnancy test at screening and must agree to further pregnancy tests during the study.
Exclusion Criteria
-
Prior or concurrent exposure to any of the following in the specified time frame prior to the first dose of Elra treatment:
- Within 14 days or at least 5 half-lives, whichever is less, of any investigational treatment
- Within 7 days of IMIDs, PI, anti-CD38 mAb, or cytotoxic systemic myeloma therapies
- Within 12 weeks of autologous stem-cell therapy (ASCT) or 6 months of AlloSCT and has to be off immunosuppressive agents >=42 days without signs of graft versus host disease (GVHD)
- Within 2 weeks of major surgery
- Within 6 months of cerebrovascular accident (CVA) events
-
Waldenstrom, POEMS, Amyloidosis, ongoing plasma cell leukemia (PCL)
-
History of Human Immunodeficiency Virus (HIV)
-
Active, uncontrolled HBV infection despite antiviral therapy.
-
Uncontrolled cardiac, pulmonary, gastrointestinal (GI), hepatic, renal, central nervous system(CNS) diseases not due to myeloma, at the discretion of investigator, that are not a candidate for T cell engager (TCE) therapy
-
Uncontrolled or recurrent infections
-
Autoimmune disease requiring systemic treatment (except for low dose steroids, equivalent to 10mg/day or less of prednisone)
-
Disabling psychiatric conditions, substance abuse (alcohol, or drug), dementia, altered mental status
-
Any other active malignancies within 5 years of completing treatment (with the exception of hormonal therapies for breast or prostate cancer) and >minimal risk of recurrence
-
Myelodysplastic syndromes (MDS)
-
Any issues that may impair the ability of the participant to receive or tolerate the planned treatment, to understand the informed consent, or any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that would prevent, limit, or confound the protocol specified assessments.
-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Elra or other agents used in study.
-
History or possible non-compliance with recommended treatments
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Treatment with Elranatamab (SubQ) Q4W
To evaluate the efficacy of RT-induced immune priming to enhance Elranatamab (Elra) in RRMM with EMD or PMD as measured by overall response rate |
Given by IV |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Safety and adverse events (AEs)
時間枠:Through study completion; an average of 1 year
|
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 |
Through study completion; an average of 1 year
|
協力者と研究者
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。